D-0727-2026 Class II Ongoing
FDA drug recall D-0727-2026 was initiated by Fresenius Kabi USA, LLC on Jul 16, 2026 and is designated Class II. Reason for recall: Presence of Particulate Matter: Hair was found in products The recall status is ongoing. Affected quantity: 92,600 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 29, 2026
- Initiation Date
- Jul 16, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 92,600 vials
Product description
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Reason for recall
Presence of Particulate Matter: Hair was found in products
Distribution pattern
Nationwide within in the USA
Code information
Lot #: 6133436, Exp. Date 10/2028
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0727-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026